Skip to content

Draft, not yet released. In stewardship review. Not indexed until the first approved release.

References and record

Every source the edition rests on, the publication record, the corrections log and the open record.

16 min read0 figures1 table0 notesNR-XTECH-SYNBIO-GLOBAL-2026-BASELINE

Inhalt
  1. ·Edition home
  2. ·Executive summary
  3. 1Synthetic biology is a build capability and a governance test
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
  7. 5Design capability outpaces screening and oversight
  8. 6Readings from the other desks
  9. 7The 2027 agenda
  10. 8Systems in depth
  11. AMethodik
  12. BData appendix
  13. CReferences and record
    1. C.1 44 sources
    2. C.2 Publication record
    3. C.3 Corrections log
    4. C.4 Open record
    5. C.5 Where this edition sits among the six pillars
  14. ·Complete edition, for print

C.144 sources

NR-CIT-1, editor first. A DOI is linked where the source has one; Nexus records carry a UNI once the catalogue allocates it (NS-1).

  1. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 7, chapter 8
  2. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 8
  3. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 8
  4. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  5. 5Gibson, D.G. et al., Creation of a bacterial cell controlled by a chemically synthesised genome, Science 329 (5987), 52 to 56, 2010 (record read via Europe PMC: 1.08 million base pair genome). American Association for the Advancement of Science, Washington. Observation year 2010. Accessed 2026-11-03. Cited in chapter 2, chapter 6
  6. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  7. 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  8. 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6
  9. 9US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3
  10. 10Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03. Cited in chapter 2, chapter 6
  11. 11Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03. Cited in chapter 3, chapter 4, chapter 6
  12. 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 4, chapter 6
  13. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 5, chapter 6, chapter 7, chapter 8
  14. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  15. 15Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03. Cited in chapter 2, chapter 6, chapter 8
  16. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  17. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  18. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  19. 19OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03. Cited in chapter 2, chapter 4, chapter 6
  20. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  21. 21World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03. Cited in chapter 4, chapter 6, chapter 8
  22. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
  23. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03. Cited in chapter 1, chapter 3, chapter 4, chapter 6, chapter 8
  24. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 3, chapter 4, chapter 6, chapter 8
  25. 25National Science and Technology Council, Fast Track Action Committee on Synthetic Nucleic Acid Procurement Screening (ed.), Framework for Nucleic Acid Synthesis Screening (version 1 April 2024, revised September 2024; framework document read). Office of Science and Technology Policy, Washington. Observation year 2024. Accessed 2026-11-05. Cited in chapter 2, chapter 4, chapter 6, chapter 8
  26. 26The White House (ed.), Executive Order 14292 of 5 May 2025, Improving the Safety and Security of Biological Research, Federal Register 2025-08266, 8 May 2025 (text read; section 4(b) gives OSTP 90 days to revise or replace the 2024 Framework for Nucleic Acid Synthesis Screening). Office of the Federal Register, Washington. Observation year 2025. Accessed 2026-11-05. Cited in chapter 2, chapter 4, chapter 5, chapter 6, chapter 7, chapter 8
  27. 27Congressional Research Service (ed.), Artificial Intelligence and Biosecurity Issues, CRS In Focus IF13269, 16 July 2026, updated 3 August and 15 September 2026 (all three versions read; the July version states that CRS could not determine whether the 2024 policy and the 2024 screening framework had been revised or replaced; the September update states that a July 2026 policy replaced the 2024 dual-use research policy and that OSTP had not updated the 2024 screening framework). Library of Congress, Washington. Observation year 2026. Accessed 2026-11-05. Cited in chapter 2, chapter 4, chapter 6, chapter 7, chapter 8
  28. 28European Commission (ed.), Proposal for a Regulation on establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health (European Biotech Act), COM(2025) 1022 final, 2025/0406 (COD), Strasbourg, 16 December 2025 (proposal text read from the copy transmitted to the Austrian Parliament; health biotechnology investment pilot with the European Investment Bank Group; 12-month extension of the supplementary protection certificate; chapter on biodefence and preventing biotechnology misuse). European Commission, Brussels. Observation year 2025. Accessed 2026-11-05. Cited in chapter 2, chapter 6, chapter 8
  29. 29European Parliament (ed.), Legislative Train Schedule: European Biotech Act II (edition of 20 September 2026 read; status announced; Commission work programme 2026 indicative date Q3 2026; would broaden the health-focused Act I to industrial biotechnology and biomanufacturing). European Parliament, Brussels. Observation year 2026. Accessed 2026-11-05. Cited in chapter 2, chapter 6
  30. 30Engineering Biology Research Consortium (ed.), Nucleic Acid Synthesis Screening elements of EO 14292: Improving the Safety and Security of Biological Research, compiled and edited by R. Mackelprang, June 2025 (document read; recommendations for the updated framework OSTP was to develop under the order). EBRC, Emeryville. Observation year 2025. Accessed 2026-11-05. Cited in chapter 2
  31. 31International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol v3.1, 1 June 2026 (document read; common sequence and customer screening practice of IGSC members). IGSC. Observation year 2026. Accessed 2026-11-05. Cited in chapter 4, chapter 6
  32. 32Department for Science, Innovation and Technology (ed.), UK screening guidance on synthetic nucleic acids for users and providers, 8 October 2024 (guidance page read). DSIT, London. Observation year 2024. Accessed 2026-11-05. Cited in chapter 4, chapter 6
  33. 33National Academies of Sciences, Engineering, and Medicine (eds.), Biodefense in the Age of Synthetic Biology, 2018 (record read via Crossref, doi 10.17226/24890; consensus study by the Committee on Strategies for Identifying and Addressing Potential Biodefense Vulnerabilities Posed by Synthetic Biology). National Academies Press, Washington. Observation year 2018. Accessed 2026-11-05. doi:10.17226/24890 Cited in chapter 6
  34. 34United Nations Office for Disarmament Affairs (ed.), Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction (treaty page read; opened for signature 10 April 1972; in force since 26 March 1975; 189 States Parties). UNODA, New York. Observation year 1972. Accessed 2026-11-05. Cited in chapter 6
  35. 35Secretariat of the Convention on Biological Diversity (ed.), The Cartagena Protocol on Biosafety to the Convention on Biological Diversity (protocol page read; adopted 29 January 2000; in force since 11 September 2003; governs living modified organisms). CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-05. Cited in chapter 4, chapter 6, chapter 8
  36. 36International Organization for Standardization (ed.), ISO 20688-2:2024, Biotechnology, Nucleic acid synthesis, Part 2: Requirements for the production and quality control of synthesised gene fragments, genes, and genomes (approved 15 March 2024; catalogue record and scope read via a national standards store). ISO, Geneva. Observation year 2024. Accessed 2026-11-05. Cited in chapter 6, chapter 8
  37. 37McKinsey Global Institute (ed.), The Bio Revolution: Innovations transforming economies, societies, and our lives, May 2020 (executive summary read; no figure used). McKinsey and Company, New York. Observation year 2020. Accessed 2026-11-05. Cited in chapter 6, chapter 8
  38. 38Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 337 (6096), 816 to 821, 2012 (record read via Crossref). American Association for the Advancement of Science, Washington. Observation year 2012. Accessed 2026-11-05. Cited in chapter 6
  39. 39Gibson, D.G. et al., Enzymatic assembly of DNA molecules up to several hundred kilobases, Nature Methods 6 (5), 343 to 345, 2009 (record read via Crossref). Springer Nature, London. Observation year 2009. Accessed 2026-11-05. Cited in chapter 6
  40. 40Ro, D.-K. et al., Production of the antimalarial drug precursor artemisinic acid in engineered yeast, Nature 440, 940 to 943, 2006 (record read via Crossref). Springer Nature, London. Observation year 2006. Accessed 2026-11-05. Cited in chapter 6
  41. 41Elowitz, M.B. and Leibler, S., A synthetic oscillatory network of transcriptional regulators, Nature 403 (6767), 335 to 338, 2000 (record read via Crossref). Springer Nature, London. Observation year 2000. Accessed 2026-11-05. Cited in chapter 6
  42. 42Gardner, T.S., Cantor, C.R. and Collins, J.J., Construction of a genetic toggle switch in Escherichia coli, Nature 403 (6767), 339 to 342, 2000 (record read via Crossref). Springer Nature, London. Observation year 2000. Accessed 2026-11-05. Cited in chapter 6
  43. 43Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017 (record read via Crossref). American Association for the Advancement of Science, Washington. Observation year 2017. Accessed 2026-11-05. Cited in chapter 2, chapter 6, chapter 8
  44. 44Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, bioRxiv preprint 2025.05.02.651837, posted 2 May 2025 (record and abstract read via Crossref; preprint of the Science article [1]; not peer-reviewed). Cold Spring Harbor Laboratory, New York. Observation year 2025. Accessed 2026-11-05. Cited in chapter 2, chapter 6

C.2Publication record

Veröffentlichung

Titel
Exponential Technology Report 2026: Synthetic Biology and Bioengineering, Baseline Edition
Serien
Reports · Exponential Technology Series XT-04
Ausgabe
Baseline Edition 2026 · inaugural annual
Version
v1.0.0 · draft for stewardship review
Publication ID
NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-v1.0.0
Evidenzschluss
30 September 2026
Publication date
Oktober 2026
DOI
concept and version DOI at deposit

Herausgeber

Maßgeblicher Herausgeber
The Global Centre for Risk and Innovation (GCRI), for the Nexus Consortium
Ort
Toronto
Redaktion
Saeed Valadbaygi, Chief Steward and Managing Editor
Sachwalter
GCRI · technical truth · the Global Risks Forum (GRF) · public meaning · the Global Risks Alliance (GRA) · capital meaning
Lizenz
text CC BY 4.0; data on the terms of each source
Copyright
© 2026 GCRI · Nexus Consortium
Sprache
English (en-GB) source edition
Correspondence
Registry correction pathway · editorial office

Colophon

Format
A4 portrait · screen, print and archival PDF
Typefaces
Space Grotesk (display) · Geist (text) · IBM Plex Sans Italic (standfirsts) · IBM Plex Mono (data)
Design standard
Reports Foundational Edition, Volume I, Part VII
Barrierefreiheit
tagged PDF and HTML targets; text alternatives for every figure
Produktion
Reports editorial team, GCRI

Release path for this version

Table C.1Release path for this version
SchrittWas geschiehtWann
Entwurfeditorial self-check complete at evidence closeOktober 2026
Steward reviewfive passes on the exact draft (keys T · M · F · N)Q4 2026
Genehmigungpublication authority approves the exact digestbefore release
Depositconcept and version DOI minted; registry pointer setat release
Nachfolgethe 2027 synthetic biology edition reports changes against this baseline2027
Current version
v1.0.0 draft, stewardship review
Previous edition
none, first edition of the series
Next edition
NR-XTECH-SYNBIO-GLOBAL-2027-v1.0.0
Latest version
resolve the concept DOI or the registry record
Correction route
Registry correction pathway
Notice types
erratum · addendum · supersession · withdrawal

C.3Korrekturprotokoll

0correction notices. No edition has been released yet, so none can be corrected; the log below lists each edition’s current version.

AusgabeVersionDateStatusVeränderungNotice
XT-04NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-v1.0.0Oktober 2026EntwurfBaseline Edition 2026, inaugural annual edition,Keine

Notice types: erratum, addendum, supersession, withdrawal. A correction is a new version with a published notice; the earlier version stays resolvable, and no edition is ever edited in silence.

C.4Open record

This edition’s open record

Publication ID
NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-v1.0.0
Desk identifier and series alias
NR-GCRI-XT-04-2026-BASELINE-v1.0.0 · NR-XTC-XT-04-2026-BL
Collection
NR-COL-2026-BASELINE (IsPartOf at deposit)
DOI
Concept and version DOI at deposit, on Zenodo with DataCite metadata
Versionen
Each correction is a new version (isNewVersionOf); the concept DOI resolves to the latest
Bundle
RO-Crate 1.2 with CITATION.cff, CodeMeta and PROV-O provenance; a signed manifest
Lizenz
CC BY 4.0 (SPDX CC-BY-4.0) for original material; metadata CC0 1.0

Credit and identity

ORCID
Your iD in the deposit and the contribution record; DataCite can then add the work to your ORCID record
ROR
Your organisation by its ROR identifier, never by a typed name alone
CRediT
Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualisation, Writing, review and editing
Konto
None needed to contribute; never a password

Find and follow

Search the open indexes for Synthetic Biology and Bioengineering; software is cited by its SWHID from Software Heritage, and a quantified scenario run is preregistered on OSF before it is run. Annotation is your choice: Hypothesis opens this page in its own viewer.

Mirrors and harvest

The DOI is canonical. At release each signed bundle is also given an IPFS content identifier and a bloxberg anchor as mirrors; both are listed in the record once they exist. Zenodo exposes every record over OAI-PMH, and reviews and endorsements can arrive through COAR Notify where the repository supports it.

InvenioRDM metadata for a contribution on Synthetic Biology and Bioengineering, prefilled from this page
{
  "metadata": {
    "resource_type": {
      "id": "dataset"
    },
    "title": "Evidence on Synthetic Biology and Bioengineering for Nexus Reports",
    "publication_date": "YYYY-MM-DD",
    "creators": [
      {
        "person_or_org": {
          "type": "personal",
          "family_name": "Your family name",
          "given_name": "Your given name",
          "identifiers": [
            {
              "scheme": "orcid",
              "identifier": "0000-0000-0000-0000"
            }
          ]
        },
        "affiliations": [
          {
            "id": "ROR identifier of your organisation"
          }
        ]
      }
    ],
    "description": "What it is, where its record is kept and how it bears on Exponential Technology Report 2026: Synthetic Biology and Bioengineering.",
    "rights": [
      {
        "id": "cc-by-4.0"
      }
    ],
    "subjects": [
      {
        "subject": "Nexus Reports"
      },
      {
        "subject": "Synthetic Biology and Bioengineering"
      },
      {
        "subject": "Exponential Technology Report · XT-04"
      }
    ],
    "related_identifiers": [
      {
        "identifier": "https://therisk.global/nexus-reports/editions/xt-04/",
        "scheme": "url",
        "relation_type": {
          "id": "issupplementto"
        },
        "resource_type": {
          "id": "publication-report"
        }
      }
    ],
    "version": "1.0.0"
  },
  "custom_fields": {},
  "access": {
    "record": "public",
    "files": "public"
  },
  "files": {
    "enabled": true
  },
  "parent": {
    "communities": {
      "default": "nexusreports"
    }
  }
}

C.5Where this edition sits among the six pillars

Foundry seals the evidence and Universe tests it; Reports publishes it; Standards takes its corrections and Academy teaches from it.

  1. F03 Sealed observations and indicator series Foundry Sealed observations and indicator series behind a profile (closeout).
  2. F04 After-action and scenario findings for Universe After-action and scenario findings for chapters 10 and 13 (after action review).
  3. F05 National Portfolio movement for chapter Foundry National Portfolio movement for chapter 11 (after action review).
  4. Applied in editions Standards Nexus Standards: applied in editions.
  5. XT-04 edition Reports Synthetic Biology and Bioengineering 2026, published in every format with its sources, citation and corrections.
  6. F06 Method and correction findings as change Standards Method and correction findings as change proposals (correction).
  7. F12 Q4 synthesis informs the next-year Universe Q4 synthesis informs the next-year mandate (renewal).
  8. Taught in the open Academy Risk Academy: taught in the open.

What Foundry and Universe hand to this edition, and what it hands to Standards, Universe and Academy. From the programme spine; XT-04 is a drafted Baseline Edition, so these handoffs run from its first operational quarter.

ÜbergabeBetweenWhat crosses, and when
F03Foundry to ReportsSealed observations and indicator series behind a profile (closeout).
F04Universe to ReportsAfter-action and scenario findings for chapters 10 and 13 (after action review).
F05Foundry to ReportsNational Portfolio movement for chapter 11 (after action review).
RingNexus Standards to ReportsNexus Standards: applied in editions.
F06Reports to Nexus StandardsMethod and correction findings as change proposals (correction).
F12Reports to UniverseQ4 synthesis informs the next-year mandate (renewal).
RingReports to Risk AcademyRisk Academy: taught in the open.

Downloads

Draft, not yet releasedReview copies of a draft in stewardship review. The released edition carries its DOI and replaces them.

  • Drucken

    • PDF, A4

      The designed print edition, A4: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF116 pages1.1 MBTagged, with bookmarks

      SHA-256 639c56cefb1949003c7c12afb373872ca06a7a9d2636ed3a03036421f5a0667e

    • PDF, US Letter

      The designed print edition, US Letter: cover, imprint and licence, how to cite, contents with page numbers, every chapter, figure, table and annex.

      PDF124 pages1.1 MBTagged, with bookmarks

      SHA-256 809ea48a7122779a508bafef6382f20f37c4aec32bc811e35c132e78757714e8

  • Web edition

  • Datenbündel

    • Indicators, CSV

      21 indicators with unit, year, status and source

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-indicators.csv2 KB

      SHA-256 ad80b1f5ddbd91cc3df1a06ae20fc038c8db1504b94d5d927e92cf4654cd1ef9

    • Indicators, JSON

      The same indicators with the edition’s identity and licence

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-indicators.json3 KB

      SHA-256 42ed0ca7518f347165dbd95fe4869ad99cc319a622d910a46b91989f1f5b7e08

    • Findings, CSV

      12 findings with status, evidence-quality level and references

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-findings.csv4 KB

      SHA-256 1adaa8152308fb73ac5dd085a986cd24ce190e4728716aa4ff4a1b50a4e68f87

  • Citation files

    • Citation, BibTeX

      For LaTeX and reference managers

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE.bib1 KB

      SHA-256 ea099771745b82b9d4f32643f1660d265a4d736b13c87edd7f1d406f3f019d07

    • Citation, RIS

      For Zotero, EndNote and Mendeley

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE.ris1 KB

      SHA-256 17ed68ee662c0db11b3426eaeb65535f5fd14473a85160734886ccf70a44423b

    • Citation, CITATION.cff

      Citation File Format 1.2.0, for GitHub, Zenodo and software catalogues

      NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE.cff1 KB

      SHA-256 0b1b02fec9505a958f1baaab6932ca483182ef925f5b68fadb22734159e1daea

Check a file with its SHA-256: shasum -a 256 <file> (macOS, Linux) or Get-FileHash <file> (Windows). Text, tables and figures by Nexus: CC BY 4.0; each source keeps its own licence.

Cite this annex

Valadbaygi, S. (Ed.). (2026). Annex C: References and record. In Exponential Technology Report 2026: Synthetic Biology and Bioengineering (Baseline Edition 2026, Report No. NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

BerichteBeitragen

Send evidence or a correction on Synthetic Biology and Bioengineering.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the GCRI Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

Redaktion Systems Evidence von GCRIExponentielle Technologie

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.